Investigating the Trajectories of Association Between Biomarkers and Cancer-Related Cognitive Impairment in Patients with Breast Cancer: A Systematic Review
Cancers · 31.10.2025 · 17 (21) · 3522
DOI: 10.3390/cancers17213522 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.10.2025. Verfasst von Angela Boschetti und 6 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS San Camillo Hospital, 30126 Venice, Italy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Background/Objectives: Cancer-related cognitive impairment (CRCI) is a frequent and clinically significant consequence of breast cancer (BC) and its treatments. With rapidly evolving therapeutics and a growing body of biomarker research, a BC-specific synthesis is needed. This review aimed to evaluate associations between blood- and saliva-based biomarkers and objective and patient-reported cognitive outcomes in adults with non-metastatic BC, while accounting for treatment modality and assessment timing.
Methods
This systematic review followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and was pre-registered in the International Prospective Register of Systematic Reviews (PROSPERO, ID: CRD420251079969). PubMed, Embase, and Web of Science were searched for articles published up until April 2025. Eligible studies included adults with BC that investigated associations between blood and/or saliva biomarkers and cognitive outcomes.
Results
A total of 53 studies met inclusion criteria: 31 examined biochemical biomarkers; 17, genetic; and 5, both. Assessments were predominantly post-treatment. Baseline measures were more infrequent. Chemotherapy (ChT) predominated, while endocrine therapy (ET) and radiotherapy (RT) were variably examined. Targeted therapies and immunotherapies were rarely included. IL-6 and TNF-α were most consistently linked to poorer cognition, although results varied by timing and assessment type. CRP and derived indices showed intermittent associations. Stress-axis markers and BDNF were mainly related to subjective outcomes. Genetic findings implicated DNA repair and oxidative stress pathways, while APOE, COMT, and BDNF results were inconsistent.
Conclusions
Evidence for biomarker correlates of CRCI in BC is highly heterogeneous. Longitudinal, harmonized, and treatment-specific studies are needed to establish reproducible biomarker panels for risk stratification and targeted intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRCCS San Camillo Hospital, 30126 Venice, Italy.
ORCID-Profile: Angela Boschetti, Laura Danesin, Elisa Bevilacqua, Pierfranco Conte, Francesca Burgio
Förderung
- Ministero della Salute
Zitieren
APA
Boschetti, A., Danesin, L., Bevilacqua, E., Giada, R., Gion, M., Conte, P., & Burgio, F. (2025). Investigating the Trajectories of Association Between Biomarkers and Cancer-Related Cognitive Impairment in Patients with Breast Cancer: A Systematic Review. Cancers, 17(21), 3522. https://doi.org/10.3390/cancers17213522
Vancouver
Boschetti A, Danesin L, Bevilacqua E, Giada R, Gion M, Conte P, et al. Investigating the Trajectories of Association Between Biomarkers and Cancer-Related Cognitive Impairment in Patients with Breast Cancer: A Systematic Review. Cancers. 2025;17(21):3522. doi:10.3390/cancers17213522
BibTeX
@article{Boschetti2025,
author = {Boschetti, Angela and Danesin, Laura and Bevilacqua, Elisa and Giada, Riccardo and Gion, Massimo and Conte, Pierfranco and Burgio, Francesca},
title = {Investigating the Trajectories of Association Between Biomarkers and Cancer-Related Cognitive Impairment in Patients with Breast Cancer: A Systematic Review},
journal = {Cancers},
year = {2025},
volume = {17},
number = {21},
pages = {3522},
doi = {10.3390/cancers17213522}
}
EUVIMED